Robert E. Claypoole's most recent trade in Bioventus Inc - Ordinary Shares - Class A was a trade of 93,750 Class A Common Stock done . Disclosure was reported to the exchange on Jan. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bioventus Inc (Class A) | Robert E. Claypoole | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 93,750 | 158,714 (0%) | 0% | 0 | Class A Common Stock | |
| Bioventus Inc (Class A) | Robert E. Claypoole | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2026 | 93,750 | 187,500 | - | - | Restricted Stock Units | |
| Bioventus Inc (Class A) | Robert E. Claypoole | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.03 per share. | 09 Jan 2026 | 41,717 | 116,997 (0%) | 0% | 8.0 | 334,988 | Class A Common Stock |
| Bioventus Inc (Class A) | Robert E. Claypoole | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.10 per share. | 13 Jan 2025 | 28,786 | 64,964 (0%) | 0% | 9.1 | 261,953 | Class A Common Stock |
| Bioventus Inc (Class A) | Robert E. Claypoole | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 93,750 | 93,750 (0%) | 0% | 0 | Class A Common Stock | |
| Bioventus Inc (Class A) | Robert E. Claypoole | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2025 | 93,750 | 281,250 | - | - | Restricted Stock Units | |
| Bioventus Inc (Class A) | Robert Claypoole E. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 850,000 | 850,000 | - | - | Stock Option (Right to Buy) | |
| Bioventus Inc (Class A) | E. Claypoole Robert | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 375,000 | 375,000 | - | - | Restricted Stock Units |